Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Related Articles by Review for PubMed (Select 16382061)

1.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

2.
3.

Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.

Scott LJ, Keam SJ.

Drugs. 2006;66(3):353-62. Review.

PMID:
16526826
4.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

5.

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

Monnier AM.

Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.

PMID:
17492927
6.

Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

Wardley AM.

Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.

PMID:
19096768
8.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
9.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
10.

Anti-tumor effects of letrozole.

Miller WR, Anderson TJ, Dixon JM.

Cancer Invest. 2002;20 Suppl 2:15-21. Review.

PMID:
12442345
11.

Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

Aapro MS, Forbes JF.

Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. Review.

PMID:
14535530
12.
13.

Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.

Koeberle D, Thuerlimann B.

Expert Rev Anticancer Ther. 2006 Jan;6(1):5-10. Review.

PMID:
16375638
14.

Letrozole: a review of its use in postmenopausal women with breast cancer.

Simpson D, Curran MP, Perry CM.

Drugs. 2004;64(11):1213-30. Review.

PMID:
15161328
15.

Reducing the risk of late recurrence in hormone-responsive breast cancer.

Cufer T.

Ann Oncol. 2007 Sep;18 Suppl 8:viii18-25. Review.

16.

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.

Kaufmann M, Rody A.

J Cancer Res Clin Oncol. 2005 Aug;131(8):487-94. Epub 2005 May 25. Review.

PMID:
15915367
17.

The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.

Pennery E.

Eur J Oncol Nurs. 2008 Jul;12(3):233-43. doi: 10.1016/j.ejon.2008.01.007. Epub 2008 Mar 26. Review.

PMID:
18372213
18.
19.

Continuing with letrozole offers greater benefits.

Jänicke F.

J Cancer Res Clin Oncol. 2007 Jul;133(7):445-53. Epub 2007 Jan 17. Review.

PMID:
17226047
20.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk